|
|
|
|
||
Re: Sorry if already asked and answered.... From page 165 of the S-4: "A U.S. holder’s initial aggregate tax basis in Bristol-Myers Squibb common stock received in the merger will equal the fair market value of the Bristol-Myers Squibb common stock as of the date of the merger. The holding period of the Bristol-Myers Squibb common stock received in the merger will begin on the day after the merger." The S-4 is available here, dated Feb. 1: https://www.bms.com/investors/financial-reporting/sec-filings.html |
return to message board, top of board |